scholarly journals The effectiveness and the consequences of the use of recombinant bovine somatotropin

2018 ◽  
Vol 48 (1) ◽  
pp. 9
Author(s):  
C. N. BROZOS (Χ. Ν. ΜΠΡΟΖΟΣ) ◽  
Ph. SARATSIS (Φ. ΣΑΡΑΤΣΗΣ)
Keyword(s):  
Growth Hormone ◽  
Dairy Cattle ◽  
Milk Yield ◽  
Dominant Role ◽  
Bovine Somatotropin ◽  
Recombinant Bovine Somatotropin ◽  
Commercial Use ◽  
Body Tissues

Growth hormone (also known as somatotropin) plays a dominant role on the development and metabolism of mammalians. Since the early 1950's it has been known that the administration of somatotropin in milk productive animals leads to an increase in milk yield. Nevertheless, its high cost of manufacture didn't allow the massive application, until recently. Genetic engineering achieved the production of recombinant bovine somatotropin (bST) and therefore has permitted the commercial use. Numerous of publications confirm a 10-30% increase in dairy cattle milk yield after bST administration. The mechanism of action of bST involves a series of orchestrated changes in the metabolism of body tissues so that more nutrients can be used for milk synthesis. Long-term bST administration has no effects on animal welfare. The reproductive system od bST treated cows seems to be prone to disorders. These disorders have been found to be insignificant. Advanced quality of management is necessary to accomplish maximum bST response in dairy cattle. BST is homologous to that of sheep and therefore can be successfully used in ewes as well. Due to the large number of dairy ewes in Greece, this is of great importance to Greek animal industry.

scholarly journals Extension model of lactation curves to evaluate the effect of the recombinant bovine somatotropin on milk yield in Holstein cows

2010 ◽  
Vol 62 (1) ◽  
pp. 124-129
Author(s):  
A. Palacios-Espinosa ◽  
J.L. Espinoza-Villavicencio ◽  
R. de Luna ◽  
A. Guillén ◽  
N.Y. Avila
Keyword(s):  
Growth Hormone ◽  
Dairy Cattle ◽  
Milk Yield ◽  
Bovine Somatotropin ◽  
Holstein Cows ◽  
Subcutaneous Injections ◽  
Recombinant Bovine Somatotropin ◽  
Extension Model ◽  
Lactation Curve ◽  
Wood Model

An extension model of lactation curves was used to determine the effect of recombinant bovine somatotropin (bST-r) on milk yield in Holstein dairy cattle. This model use the fitted values obtained by the Wood model, and was tested on the records of 66 cows. The milk yield predicted with the extension model and the observed yield were compared and no significant differences were observed (P>0.05). Once the extension model was validated, the milk yield tests of 199 cows were used. The cows received bST-r 500mg by subcutaneous injections. The injections were applied after 100 days in milk at 14-day intervals (seven injections). The observed milk yield was compared with the yield expected by the extension model. An increase of 5.3% was observed in milk yield in response to the bST-r. This increase is lower than that reported in the literature in response to the growth hormone in dairy cattle. It is concluded that extension model used in the present work is reliable for extending the lactation curve in Holstein cows, and the increase in milk yield in response to the application of bST-r, determined in the same animal using the extension model, was lower than that reported by other authors.

scholarly journals Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland

2020 ◽  
Author(s):  
Sylvère Störmann ◽  
Jochen Schopohl ◽  
Catharina Bullmann ◽  
Christoph Terkamp ◽  
Mirjam Christ-Crain ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
Growth Factor ◽  
Real World ◽  
Insulin Like Growth Factor ◽  
Biochemical Control ◽  
Factor I ◽  
Lanreotide Autogel

Abstract Background Evidence from controlled trials has shown that lanreotide autogel is effective in achieving biochemical and symptom control in patients with acromegaly. However, it is important to better understand the real-world patient population receiving lanreotide autogel treatment. Methods In this non-interventional study the long-term treatment response to lanreotide autogel in adult patients with acromegaly from office-based centers or clinics in Germany, Austria and Switzerland was studied. Assessments included growth hormone and insulin-like growth factor-I levels, symptoms, quality of life, lanreotide plasma levels and tumor somatostatin receptor subtype expression. The primary endpoint was achievement of full biochemical control, defined as growth hormone ≤2.5 µg/L and insulin-like growth factor I normalization at month 12. Results 76 patients were enrolled from 21 sites. 7/51 (13.7%) patients of the efficacy population had full biochemical control at baseline, 15/33 (45.5%) at month 12 and 10/26 (38.5%) at month 24 of treatment. At 12 months of treatment higher rates of biochemical control were observed in the following subgroups: older patients (>53 years [median]), females, treatment-naïve patients, and patients with a time since diagnosis of longer than 1.4 years (median). No clinically relevant differences in acromegaly symptoms or quality of life scores were observed. Median fasting blood glucose and glycated hemoglobin levels remained unchanged throughout the study. No new safety signals were observed. Overall tolerability of treatment with lanreotide autogel was judged by 80.8% of the enrolled patients at month 12 as ‘very good’ or ‘good’. Conclusion Treatment with lanreotide autogel in a real-world setting showed long-term effectiveness and good tolerability in patients with acromegaly.

scholarly journals Effect of growth hormone on milk yield and reproductive performance of subfertile Holstein cows during extended lactations

2019 ◽  
Vol 17 (1) ◽  
pp. e0403 ◽  
Author(s):  
Jessica Flores ◽  
José E. García ◽  
Jesús Mellado ◽  
Leticia Gaytán ◽  
Ángeles De Santiago ◽  
...  
Keyword(s):  
Milk Yield ◽  
Reproductive Performance ◽  
Bovine Somatotropin ◽  
Holstein Cows ◽  
Control Group ◽  
Recombinant Bovine Somatotropin ◽  
Northern Mexico ◽  
Lactation Length ◽  
Hot Environment ◽  
Farm Efficiency

The objective of this study was to determine the effects of the administration of recombinant bovine somatotropin (rbST) throughout lactation to high-yielding subfertile (conception > 270 days postpartum) Holstein cows undergoing extended lactations (≥480 d) on milk production and reproductive performance. The study used two large adjacent commercial herds with similar management in a hot area of northern Mexico (25° N). Cows in one herd (n=2341) received a 500-mg dose of rbST every 14 d until dried off, starting 60 days postpartum. The other herd served as control (n=984). Across parity, rbST-treated cows produced 20% greater milk yield than control cows in 305-d lactations. Across parities, milk yield from 305 d postpartum to the end of lactation was 2734 kg higher in rbST-treated cows than control cows. Across parities rbST-treated cows produced 4777 more kg of milk during the entire lactation (mean 605 d) than the control group (mean 572 d). Conception rates (CR) at first service were only 3.2% and 5.9% (p<0.05) for control and rbST-treated cows, respectively. Overall CR was 43.5% and 61.6% (p<0.05) for control and treated cows, respectively. Control cows required 2.4 more (p<0.01) services per conception than rbST-treated cows. It was concluded that in this hot environment, the use of rbST suits dairy producers because it substantially improves both milk yield and reproductive performance in subfertile high-yielding Holstein cows. By markedly increasing lactation length and lactation persistency farm efficiency is greatly improved due to extended herd life.

Growth hormone replacement for patients with adult onset growth hormone deficiency—what have we learned?

2004 ◽  
Vol 16 (4) ◽  
pp. 1-6
Author(s):  
Monique Piersanti
Keyword(s):  
Growth Hormone ◽  
Gh Deficiency ◽  
Hormone Replacement ◽  
Hormone Deficiency ◽  
Pituitary Hormone ◽  
Adult Onset ◽  
Gh Replacement ◽  
Term Benefit

Growth hormone (GH) deficiency is a condition recognized to occur in individuals who have had multiple pituitary hormone deficiencies as a result of pathological processes or neurosurgical interventions. The indications, benefits, and risks of GH replacement therapy will be reviewed with an emphasis on those patients who were adults with the deficiency first emerged. The results of this analysis indicate that, although a measurable improvement can be detected in the patient's quality of life, body composition, and some cardiovascular parameters, the larger questions of long-term benefit and patient selection currently remain unanswered.

Sign in / Sign up

Export Citation Format

Share Document